anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention describes a method that is operative within a clinical environment in which real-time locations of personnel and resources are tracked. The method begins in association with entry of a patient into the clinical environment, such as when a patient is in transit, or has been admitted, to an emergency room or to a hospital. In response, a given care guideline is identified. Using the care guideline, a set of one or more process rules, and information associated with at least one “encounter,” the system generates a patient-specific care protocol; the protocol includes a set of steps through which the patient is expected to proceed while in the clinical environment. An encounter occurs when two or more of objects (e.g., the patient, clinical personnel, and a clinical resource) are in a given physical proximity for a given time period at determined by the at least one process rule. According to the method, at least one event that occurs during at least a first step of the patient-specific care protocol is then monitored. Using information generated by the monitoring step and at least one process rule, the system then determines whether the patient moves to a next step in the patient-specific care protocol.
The invention relates to a traditional Chinese medicine for treating chronic mediastinitis. The traditional Chinese medicine is prepared from 15 weight parts of Ervatamia hainanensis Tsiang, 12 weight parts of Clerodendrum fortunatum, 14 weight parts of Striga masuria (Buch.-Ham. ex Benth.) Benth., 8 weight parts of Artemisia rupestris L., 10 weight parts of root of mucuna paohwashanica, 12 weight parts of Sagittaria sagittifolia L., 12 weight parts of Pseudodrynaria coronans (Wall. ex Mett.) Ching, 14 weight parts of fruit of tree-of-heaven ailanthus, 10 weight parts of seed of Hygrophila salicifolia (Vahl) Nees., 12 weight parts of Eryngium foetidum, 14 weight parts of Rhaphidop hora hongkongensis Shott, 12 weight parts of Platanthera japonica(Thumb.)Lindl., 10 weight parts of Vernonia cumingiana, 12 weight parts of cottonseed, 14 weight parts of root of Ceratostigma willmottianum Stapf and C. plumbaginoides Bunge, 10 weight parts of white peony root, 12 weight parts of poria cocos and 14 weight parts of Rosa laevigata Michx. A clinical experiment proves that the traditional Chinese medicine can safely and effectively treat chronic mediastinitis.
OBJECTIVE: Melorheostosis is a rare, non-hereditary, benign bone disease characterized by abnormal bone growth. Generally, melorheostosis develops during childhood or adolescence and progresses gradually over time. This disease represents a true challenge to the physician because of its variability due to location, extension of the affected bone, and involvement of associated soft tissue. Pain management, physical therapy, and surgery may be recommended, depending on the individual case. This review aims to get an overview of the latest evidence relating to epidemiology, clinical and radiographic characteristics, diagnosis, and possible therapeutic strategies for melorheostosis and describe our experience through a clinical case.
METHODS: We designed a comprehensive literature search on melorheostosis in MEDLINE (via Pubmed) up to April 2023 and reviewed reports published in international journals.
RESULTS: The purpose is to highlight the importance of a multidisciplinary approach in the management of a rare disease such as melorheostosis. We discuss the role of different physicians, including genetists, rheumatologists, physiatrists, physical therapists, and orthopedic surgeons, in providing accurate diagnoses and effective treatments. We conducted a comprehensive review of the literature on the treatment of melorheostosis to support these findings. In addition, the article presents a case study of a patient suffering from melorheostosis, focusing on difficulties in reaching a correct diagnosis and attempts towards conservative and surgical interventions. The patient underwent hip arthroplasty, and the final result was an improvement in function and a reduction in pain.
CONCLUSIONS: Managing melorheostosis can be challenging, and there is no standardized treatment for this condition at the moment.
The invention discloses a medicine for treating benign prostatic hyperplasia hypertrophy and a preparation method thereof. The medicine includes following traditional Chinese medicines: astragalus membranaceus, Chinese yam, common macrocarpium, oldenlandia diffusa, atractylodes macrocephala, poria cocos, Sichuan dioscorea septemloba, pangolin, salviae miltiorrhizae, rhizoma sparganii, curcuma zedoary, stir-fried cortex phellodendri, schisandra chinensis, semen coicis, honey-fried radix glycyrrhizae, divaricate saposhnikovia, leech and synthetic musk, while a western medicine formula includes vitamin B. The medicine is prepared through compatibility of Chinese medicines and western medicines and through reasonable preparation. The medicine is good in curative effect on the benign prostatic hyperplasia hypertrophy, is short in treatment course, can cure both exterior and interior, is high in curative rate, is not liable to cause relapse, is less in adverse reaction, is easy to prepare and is safe to use. The medicine is an excellent formula for treating the benign prostatic hyperplasia hypertrophy. Clinical experience for many years proves that the medicine is higher than 90% in curative effective rate and is 100% in total effective rate.
TAK-925, Intravenous single administration. Dose in Cohort 5 will be based on safety and tolerability in the Part 1. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
The wait and see group will not receive any intervention and will serve as a control group to determine the natural history of RCCT. If one treatment proves to be more effective then participants in the other groups will be offered that treatment after 12 months, or before, if the investigation finishes early due to an obvious group difference and a need to break randomisation codes.
BACKGROUND AND OBJECTIVE: Pruritus (also known as itch) is defined as an unpleasant and irritating sensation of the skin that provokes an urge to scratch or rub. It is well known that opioid administration can cause pruritus, which is paradoxical as itch and pain share overlapping sensory pathways. Because opioids inhibit pain but can cause itching. Significant progress has been made to improve our understanding of the fundamental neurobiology of itch; however, much remains unknown about the mechanisms of opioid-induced pruritus. The prevention and treatment of opioid-induced pruritus remains a challenge in the field of pain management. The objective of this narrative review is to present and discuss the current body of literature and summarize the current understanding of the mechanisms underlying opioid-induced pruritus, and its relationship to analgesia, and possible treatment options.
RESULTS: The incidence of opioid-induced pruritus differs with different opioids and routes of administration, and the various mechanisms can be broadly divided into peripheral and central. Especially central mechanisms are intricate, even at the level of the spinal dorsal horn. There is evidence that opioid receptor antagonists and mixed agonist and antagonists, especially μ-opioid antagonists and κ-opioid agonists, are effective in relieving opioid-induced pruritus. Various treatments have been used for opioid-induced pruritus; however, most of them are controversial and have conflicting results.
CONCLUSION: The use of a multimodal analgesic treatment regimen combined with a mixed antagonist and κ agonists, especially μ-opioid antagonists, and κ-opioid agonists, seems to be the current best treatment modality for the management of opioid-induced pruritus and pain.
SIGNIFICANCE: Opioids remain the gold standard for the treatment of moderate to severe acute pain as well as cancer pain. It is well known that opioid-induced pruritus often does not respond to regular antipruritic treatment, thereby posing a challenge to clinicians in the field of pain management. We believe that our review makes a significant contribution to the literature, as studies on the mechanisms of opioid-induced pruritus and effective management strategies are crucial for the management of these patients.
Using a locally deployed MedicalGPT, the commercially available online GPT-4o, Claude-3.5 Sonnet, GPT-4o mini, and Claude 3 Haiku, will each sequentially play the role of physicians from different departments involved in the Multi-Disciplinary Treatment Process. They will then sequentially take on the role of a summarizer to compile their recommendations into a final suggestion or treatment plan.
BACKGROUND: Spontaneous coronary artery dissection is a rare and important cause of myocardial infarction, especially in young women without other coronary artery disease. This arterial dissection can occur within or between any of the 3 layers. Its predisposing factors include connective tissue diseases (Marfone syndrome, Ehlers-Danlos syndrome), vasculitis (polyarteritis nodosa, systemic lupus erythematosus, and Kawasaki disease), atherosclerosis and fibromuscular dysplasia. Clinical presentations of spontaneous coronary artery dissection are wide spectrum from asymptomatic to acute coronary disease, sustained ventricular arrhythmia and sudden cardiac death.
CASE PRESENTATION: We describe A 33-year-old man with history of Hodgkin's lymphoma five years earlier that became a candidate for Patent foramen ovale closure due to recurrent embolic cerebrovascular accident. Before the intervention, coronary angiography incidentally showed dissection in the left main and all major coronary arteries.
CONCLUSIONS: Based on our hypothesis, chemoradiotherapy-induced arteriopathies could be consider as a predisposing factor for spontaneous coronary artery dissection.
The conditioning regimen is ATG/G-CSF based protocol (the so-called Beijing protocol). The rabbit ATG (Sangstat-Genzyme) 2.5mg/kg/day i.v., on days from - 5 to - 2 were administered.
Volunteers randomized into High-speed power training (HSPT) will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength for leg press (LP) and seated knee extension (KE) exercises.
Sepsis is a systemic inflammatory reaction syndrome caused by infections. Acute lung injury (ALI) occurs first and most frequently in patients with sepsis. Gentiopicroside (GPS), which originates mostly from Gentiana, is classified as a secoiridoid glycosides. Terpenoid glycosides have various biological effects, including liver protection, blood glucose and cholesterol level management, and anti-inflammatory and antitumor effects. However, presently, the biochemical foundation and mechanism of the anti-inflammatory effects of GPS in sepsis-induced ALI have not been explained. In the present study, we established a rat model of sepsis ALI induced by cecal ligation and puncture. This enables us to observe the effects of GPS therapy, which significantly reduced the inflammatory response (TNF-α, IL-1β, and IL-6), nitrogen stress, oxidative stress, and severity of ALI at both the whole animal and molecular levels. In addition, GPS ameliorates LPS-induced ALI via regulation of inflammatory response and cell proptosis in BEAS-2B. This study provides a theoretical basis for treating sepsis-induced ALI with GPS.
The invention relates to a traditional Chinese medicine compound preparation, and discloses a capsule for enhancing the bone mineral density. The capsule is prepared from the following components in parts by weight: 80-90 parts of cervus elaphus linnaeus powder, 20-35 parts of rhizoma drynariae extract, 20-35 parts of epimedium extract, 95-120 parts of red konjic rice powder, 50-65 parts of pregelatinized starch and 50-65 parts of silicon dioxide. The capsule for enhancing the bone mineral density is prepared from the materials with bone and muscle strengthening function, such as cervus elaphus linnaeus powder, rhizoma drynariae extract, epimedium extract and konjic rice powder, and is capable of preventing osteoporosis and enhancing bone mineral density. The capsule has a remarkable effect of enhancing bone mineral density, is high in safety, and does not have toxic or side effect. The invention further relates to a method for preparing the capsule for enhancing bone mineral density. The preparation method is simple, environmentally friendly, economical, effective and non-toxic, and has a wide application range.
All injured patients arriving by ambulance, and allocated to a red (1st) or yellow (2nd) priority category will be eligible for inclusion. Patients arriving with and without notification by the ambulance service using the pre-hospital notification application.
PROBLEM TO BE SOLVED: To provide a method for forming an embryoid body from an embryonic stem cell, with which an embryoid body can be stably formed in high efficiency even by using either a serum medium or a serum-free or even at a relatively low density of an embryonic stem cell, a method for differentiating and inducing a functional cell usable for cell and organ transplantation medical treatment from an embryonic stem cell, to obtain a medium and a differentiation inducer useful for the method, the differentiation-induced cell and to provide a method for use thereof. SOLUTION: This method for forming an embryoid body from an embryonic stem cell is characterized by comprising a process for culturing an embryonic stem cell using a medium containing a specific factor. This medium is used for the method. This differentiation inducer is used for the method. This method for differentiated cell induction using the method is provided. The differentiation- induced cell is obtained. This method for use thereof is provided.
The serratus anterior plane block will be performed under ultrasound guidance in the preoperative term. Tramadol will be administered via patient controlled analgesia (PCA) device at 20 mg bolus dose with 10 min. lockout time without basal infusion dose.
Anodal electrode (35 cm2 sponge electrode) placed over C3. Cathodal electrode (35 cm2 sponge electrode) placed over the right supraorbital area. 20 minutes of stimulation at 2 mA with a 30-second phase-in and phase-out period.
During the initiation of the inflammatory response of microglia, the expression of many inflammation- and cell metabolism-related genes alters. However, how the transcription of inflammation- and metabolism-related genes are coordinately regulated during inflammation initiation is poorly understood. In this study, we found that LPS stimulation induced the expression of the chromatin target of PRMT1 (protein arginine methyltransferase 1) (CHTOP) in microglia. Knocking down CHTOP in microglia decreased proinflammatory cytokine expression. In addition, CHTOP knockdown altered cell metabolism, as both the upregulated genes were enriched in cell metabolism-related pathways and the metabolites profile was greatly altered based on untargeted metabolomics analysis. Mechanistically, CHTOP could directly bind the regulatory elements of inflammation and cell metabolism-related genes to regulate their transcription. In addition, knocking down CHTOP increased neuronal viability in vitro and alleviated microglia-mediated neuroinflammation in a systemic LPS treatment mouse model. Collectively, these data revealed CHTOP as a novel regulator to promote microglia-mediated neuroinflammation by coordinately regulating the transcription of inflammation and cell metabolism-related genes.
The goal of this MEEI Auditory Brainstem Implant (ABI) research study is to find new ways to improve hearing in patients who are deaf and cannot receive a cochlear implant. The ABI is a surgically placed bionic implant that converts sounds into electrical signals that are directly transmitted to the cochlear nucleus, the first auditory center of the brain. For many years, ABIs have improved the hearing of patients who are deaf due to brain tumors associated with a genetic syndrome called Neurofibromatosis Type 2 (NF2). However, a number of recent studies suggest that deaf patients who do not have NF2 and are not eligible for a cochlear implant may also benefit from placement of an ABI. These preliminary studies suggest that these non-NF2 or "nontumor" patients may actually have better outcomes after ABI surgery than patients suffering from NF2. Patients who do not have NF2 and are deaf due to damage to the hearing nerves or inner ears from infection, disease or injury are not cochlear implant candidates and there are no other options to improve hearing in these cases except for the ABI. Thus, the purpose of our study is to carefully analyze whether ABI surgery improves the hearing and quality of life of non-NF2 patients based on subjective and objective measures of their hearing before and after ABI surgery. In particular, we plan to study ABI outcomes in non-NF2 patients, characterize the parameters used on their devices, and determine the safety profile of ABIs in these patients.
OBJECTIVES: I. Compare the efficacy of multi-course high-dose chemotherapy with autologous peripheral blood stem cell transplantation versus standard-dose chemotherapy in women with metastatic breast cancer. II. Compare the five year event-free survival, in terms of time to progression or time to death due to toxic effects, in patients treated with these regimens. III. Compare the response rate and overall survival of patients treated with these regimens. IV. Compare the toxicity of these regimens in this patient population.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two treatment arms. Arm I: Patients receive docetaxel and doxorubicin once followed by filgrastim (G-CSF) daily for approximately 1 week. Treatment repeats approximately every 3 weeks for 4 courses. Patients then receive cyclophosphamide, methotrexate, and fluorouracil on days 7 and 8 every 4 weeks for 4 courses. Arm II: Patients receive docetaxel, doxorubicin, and G-CSF as in arm I for 3 courses. Patients undergo leukapheresis daily for 3 or 4 days. Patients then receive 1 course of ifosfamide, etoposide, and carboplatin daily for 4 days when blood counts recover, followed by 1 course of cyclophosphamide and thiotepa daily for 4 days. Patients undergo peripheral blood stem cell reinfusion following each course.

PROJECTED ACCRUAL: A total of 264 patients (132 per arm) will be accrued for this study.
Either a medially wedged or laterally wedged footwear insole (whichever reduces knee joint mechanical loading more, as determined from subject-specific biomechanical tests), constructed using a 3D printer will be inserted into each participant's shoe. The participant will be asked to utilize this insole as much as possible throughout the day over the course of 3 months.
Diabetes Distress (DD) is the personal, often hidden side of diabetes: it reflects the unique emotional burdens and strains that individuals with diabetes may experience as they struggle to keep blood glucose levels within range. When high, DD can have a major, negative impact on disease management and glycemic control. High DD is characterized by frustration, feeling overwhelmed, and feeling hopeless and discouraged by the unceasing demands of diabetes. DD is also linked to an individual's beliefs, expectations, current life situation, and personal and social resources.

The proposed study is a three-arm, 12-month randomized comparison trial to test the added value of a DD-targeted (TunedIn) intervention vs. a unified DD and management intervention (FixIt), relative to a traditional, educational/behavioral-management intervention (StreamLine). Each of the three programs (arms) will follow a separate, standardized protocol. All participants will receive three months of intervention with nine months of follow-up.
Oral anthelmintic compositions comprise a dibutyl-lead diester of a C2-C18 fatty acid together with a non-toxic diluent or carrier. Preferred diesters are the diacetate, dihexylate, diheptylate, dioctylate, dilaurate and the dimonochloroacetate, and butyl includes normaliso-, and tert.-butyl.  The compositions may take the form of tablets, dragees, capsules, powders, and concentrated pre-mix liquid and solid formulations for addition to, respectively, drinking water and feedstuffs.  The compositions may include dispersing and wetting agents, and sweetening agents, and other growth promoters such as vitamins, minerals, and antibiotics.  Other anthelmintics may also be present, for example; dibutyltin laurate, lead arsenate, tin arsenate, phenothiazine, nicotine sulphate piperazine and 2-hydroxy-5-chloro-N-(2-chloro-4-nitrophenyl) benzamide.  The invention includes a method for treating helminthiasis in non-human animals by orally administering the compositions.
Pancreatic cancer is one of the tumors with the worst prognosis, and unlike other cancers, few advances have been made in recent years. The only curative option is surgery, but only 15-20% of patients are candidates, with a high risk of relapse. In advanced pancreatic cancer there are few first-line treatment options and no validated biomarkers for better treatment selection. The development of targeted therapies in pancreatic cancer is increasingly feasible due to tumor-agnostic treatments, such as PARP inhibitors in patients with BRCA1, BRCA2 or PALB2 alterations or immunotherapies in patients with high microsatellite instability/tumor mutational burden. In addition, other therapeutic molecules have been developed for patients with KRAS G12C mutation or fusions in NTRK or NRG1. Consequently, there has been a growing interest in biomarkers that may help guide targeted therapy in pancreatic cancer. Therefore, this review aims to offer an updated perspective on biomarkers with therapeutic potential in pancreatic cancer.
PURPOSE:To provide the titled composition containing a granular dentifrice base and a granular tasty component coated with a substance composed of shellac, a glycerol fatty acid ester and a diluent, causing dissolution of the tasty component after a definite period thereby informing the lapse of predetermined period by the change of taste. CONSTITUTION:The titled composition can be produced by mixing a granular dentifrice base with a granular tasty component coated with a coating substance containing shellac, a glycerol fatty acid ester and a diluent (e.g. sorbitol, corn starch, etc.) at weight ratios of 10:(0.1-4.0):(10-30). The granular tasty component has an average particle diameter of <=0.7mm and contains 10-40wt% coating substance. The tasty component is a sweetening substance, acidulant substance, etc. The dissolution of the tasty component from the granular tasty component takes place e.g. 30sec after application. The distinct change of taste informs the lapse of proper period of application and, accordingly, it is not necessary to repeat the interruption of use to inspect the state of dissolution.